Every antidepressant in this catalogue carries the same boxed warning, and it is about young people specifically. The label states that antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies, and that all antidepressant-treated patients should be closely monitored for clinical worsening and for the emergence of suicidal thoughts and behaviours.

That warning is easy to misread in either direction. It does not say antidepressants cause suicide, and it does not say they should not be used. What it says, and what the fuller version of the warning makes explicit, is that the risk is concentrated in a particular age group and a particular period, which is exactly why the first weeks of treatment are monitored rather than left alone.

Key takeaways

  • The boxed warning covers children, adolescents and young adults, based on short-term studies.
  • Short-term studies did not show an increased risk in adults beyond age 24, and showed a reduction in risk in adults aged 65 and older.
  • Depression itself increases suicide risk. The label says so directly, which is the context the warning sits in.
  • Patients of all ages should be monitored closely when starting, for clinical worsening, suicidality or unusual changes in behaviour.
  • Families and caregivers should be told to watch and to stay in contact with the prescriber. That instruction is on the label.
  • They take weeks to work, while side effects often appear first, which is why people stop too early.
  • Do not stop abruptly. Withdrawal symptoms are common and are not a sign of addiction.
  • The first choice is often not the final one, and switching is normal rather than failure.

What does the boxed warning actually say?

That the risk was seen in under-25s, that it was not seen in older adults, and that everyone should be monitored early in treatment.

The fuller wording, from the fluoxetine label, is worth reading in full rather than in summary:

Antidepressants increased the risk compared to placebo of suicidal thinking and behaviour in children, adolescents, and young adults in short-term studies of major depressive disorder and other psychiatric disorders. Anyone considering their use in a child, adolescent or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality in adults beyond age 24, and there was a reduction in risk in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality or unusual changes in behaviour. Families and caregivers should be advised of the need for close observation and communication with the prescriber.

Four things follow from that, and they are the practical content of the warning:

  1. Age matters. The signal is in under-25s. It is not a general adult risk, and in the over-65s the direction reverses.
  2. The untreated condition is not the safe option. The label names depression itself as carrying increased suicide risk.
  3. Monitoring is the mitigation. Not avoidance.
  4. Other people need to know. The instruction to inform families and caregivers is part of the warning, not an optional courtesy.

If you or someone you care about is starting an antidepressant, the useful action is to agree with the prescriber how the first few weeks will be checked, and to tell someone close to you what to watch for.

What happens in the first few weeks?

Side effects usually arrive before the benefit does, which is the single commonest reason people stop too early.

Antidepressants generally take several weeks to produce their full effect on mood. Nausea, headache, disturbed sleep, restlessness or increased anxiety often appear in the first days and frequently settle.

That sequence, feeling somewhat worse before feeling better, is difficult and it is where most treatment fails. Knowing it is coming makes it survivable, and it is the reason prescribers ask to see people early rather than at the end of a long first prescription.

Symptoms that should prompt contact rather than waiting:

  • new or worsening thoughts of self-harm or suicide
  • marked agitation, restlessness or an inability to sit still
  • a sudden or unusual change in behaviour, particularly in a young person
  • worsening of mood rather than the expected slow improvement

None of those means the medicine was the wrong choice. They mean the prescriber needs to know now rather than at the next scheduled appointment.

Why can I not just stop when I feel better?

Because stopping abruptly causes withdrawal symptoms, and because stopping too early is when relapse happens.

Antidepressant withdrawal, sometimes called discontinuation symptoms, can include dizziness, electric-shock sensations, nausea, sleep disturbance, irritability and flu-like symptoms. They vary a great deal between medicines and between people, and they are more likely with medicines that leave the body quickly.

Two clarifications that matter:

  • Withdrawal symptoms are not addiction. Antidepressants are not addictive in the sense of craving or dose escalation. The body adapts to their presence and needs time to adapt to their absence.
  • Feeling well is the treatment working, not evidence it is no longer needed. Continuing for a period after recovery is standard practice to reduce relapse risk, and how long depends on your history.

So the correct step when you want to stop is a conversation about tapering, on a schedule your prescriber sets. Running out is the accidental version of stopping abruptly, which makes ordering repeats early a practical safety measure rather than an administrative habit.

Are they all the same?

No, and the differences are the reason a first choice sometimes has to be changed.

The catalogue covers several groups:

  • SSRIs such as sertraline, fluoxetine, escitalopram, citalopram and paroxetine.
  • SNRIs such as venlafaxine and duloxetine, which also has a role in neuropathic pain.
  • Mirtazapine, which affects sleep and appetite differently from the SSRIs.
  • Tricyclics such as amitriptyline, also widely used at lower doses for neuropathic pain rather than depression.
  • Bupropion, which has a different mechanism again.

They differ in side effect profile, in interactions, in how quickly they leave the body and therefore in withdrawal behaviour, and in what else they help with. Someone with insomnia and poor appetite may suit a different medicine from someone with fatigue and low motivation.

Needing to switch is common and is not failure. It is one of the reasons the early review appointments exist.

What should I tell my prescriber?

Everything you take, and anything that has happened before.

Worth raising before starting:

  • any previous experience of antidepressants, including what happened
  • other medicines, including ones from another country, over-the-counter products, and supplements such as St John’s wort
  • pregnancy, or plans for it, and breastfeeding
  • any history of bipolar disorder or manic episodes, which changes the approach
  • epilepsy or seizures
  • other conditions being treated, since some antidepressants are chosen partly for their effect on pain or sleep

The interaction question matters more than people expect, because antidepressants interact with a long list of common medicines, and because people frequently do not mention supplements when asked what they take.

Do and don’t

Do:

  • Agree how the first weeks will be reviewed before you start.
  • Tell someone close to you what to watch for, as the label advises.
  • Expect side effects before benefit, and report worsening rather than enduring it.
  • Order repeats early so you never run out.
  • Discuss tapering when you want to stop.
  • Say if you have switched brands or presentation.

Don’t:

  • Don’t stop suddenly, and don’t let the supply lapse.
  • Don’t assume a slow start means the medicine has failed.
  • Don’t treat withdrawal symptoms as evidence of addiction.
  • Don’t take someone else’s antidepressant.
  • Don’t add supplements, including St John’s wort, without telling your prescriber.

Frequently asked questions

Does the boxed warning mean antidepressants are dangerous? It means a specific risk was found in a specific group and requires monitoring. The same warning states that short-term studies did not show increased risk in adults over 24, showed reduced risk in those 65 and over, and that depression itself is associated with increased suicide risk. It is an argument for close follow-up, not for going untreated.

How long before I feel better? Generally several weeks for the full effect, with side effects often appearing sooner. If nothing has changed after the period your prescriber described, that is a reason to go back rather than to give up.

Will I be on them forever? Not necessarily. Duration depends on your history and how many episodes you have had, and it is decided with your prescriber. What is not advisable is deciding to stop unilaterally at the point you feel well.

Where to go next

The antidepressants and mental health categories list what is stocked here, and the ingredients index maps active ingredients to the brands containing them, which is the reliable way to continue a prescription started in another country.

MedicForce option: our listings show active ingredient and strength, which is what you need to match when continuing existing treatment.

  • Antidepressants, NHS patient-facing guidance on how antidepressants work, side effects and stopping.

The boxed warning text quoted above is from the approved product information for fluoxetine and sertraline. The same warning appears on the labels of the other antidepressants in this catalogue.